T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer

다국어 초록 (Multilingual Abstract)

Th17 cells are a specialized subset of CD4? Tcells that are essential in driving inflammation duringautoimmune disease and infection through a signaturecytokine IL-17. Th17 cells have been found in varioushuman cancers. The function of these cells in cancers ishighly context-dependent; both tumor-promoting andtumor-suppressing activity have been reported. IL-17 andIL-22, Th17-derived cytokines, influence the tumormicroenvironment by directly promoting transformed cellproperties and neighboring stromal cell activity. Thesecytokines are also involved in regulation of the immunesystem by modulating the activities of myeloid cells and Tcells. These findings suggest that Th17 cells and theircytokines are a key mediator of cancer development, representinga potential target for cancer therapy. Herein, Ireview recent preclinical studies on the function of Th17cells and IL-17 in cancer and discuss possible therapeuticapproaches to harness Th17 cells for cancer immunotherapy.

참고문헌 (Reference)

1 Wu P, "gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer" 40 : 785-800, 2014

2 Spranger S, "Up-regulation of PD-L1, IDO, and T(regs)in the melanoma tumor microenvironment is driven by CD8(?)T cells" 5 : 200ra116-, 2013

3 Muranski P, "Tumor-specific Th17-polarized cells eradicate large established melanoma" 112 : 362-373, 2008

4 Mangan PR, "Transforming growth factor-beta induces development of the T(H)17 lineage" 441 : 231-234, 2006

5 Ivanov II, "The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17? T helper cells" 126 : 1121-1133, 2006

6 Punt S, "The correlations between IL-17 vs Th17 cells and cancer patient survival : a systematic review" 4 : 547-, 2015

7 Gaffen SL, "The IL-23-IL-17 immune axis : from mechanisms to therapeutic testing" 14 : 585-600, 2014

8 Gagliani N, "Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation" 523 : 221-225, 2015

9 Bailey SR, "Th17 cells in cancer : the ultimate identity crisis" 5 : 276-, 2014

10 Muranski P, "Th17 cells are long lived and retain a stem cell-like molecular signature" 35 : 972-985, 2011

11 Wu HH, "Targeting IL-17B-IL-17RB signaling with an anti-IL-17RB antibody blocks pancreatic cancer metastasis by silencing multiple chemokines" 212 : 333-349, 2015

12 Veldhoen M, "TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells" 24 : 179-189, 2006

13 Novitskiy SV, "TGF-beta receptor II loss promotes mammary carcinoma progression by Th17 dependent mechanisms" 1 : 430-441, 2011

14 Martin-Orozco N, "T helper 17 cells promote cytotoxic T cell activation in tumor immunity" 31 : 787-798, 2009

15 Chang SH, "T helper 17 cells play a critical pathogenic role in lung cancer" 111 : 5664-5669, 2014

16 Crespo J, "T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment" 25 : 214-221, 2013

17 Hu X, "Synthetic RORgamma agonists regulate multiple pathways to enhance antitumor immunity" 5 : e1254854-, 2016

18 Huh JR, "Small molecule inhibitors of RORgammat : targeting Th17 cells and other applications" 42 : 2232-2237, 2012

19 Savage PA, "Shaping the repertoire of tumor-infiltrating effector and regulatory T cells" 259 : 245-258, 2014

20 Pickert G, "STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing" 206 : 1465-1472, 2009

21 Esfahani K, "Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade" 376 : 1989-1991, 2017

22 Geis AL, "Regulatory T-cell response to enterotoxigenic bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis" 5 : 1098-1109, 2015

23 Savage PA, "Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8? T lymphocytes" 319 : 215-220, 2008

24 Gros A, "Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients" 22 : 433-438, 2016

25 Yamada Y, "Prevalence and clinical relevance of Th17 cells in patients with gastric cancer" 178 : 685-691, 2012

26 Phillips JD, "Preferential expansion of proinflammatory Tregs in human non-small cell lung cancer" 64 : 1185-1191, 2015

27 Hirota K, "Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses" 14 : 372-379, 2013

28 Annunziato F, "Phenotypic and functional features of human Th17 cells" 204 : 1849-1861, 2007

29 Kryczek I, "Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments" 114 : 1141-1149, 2009

30 Komatsu N, "Pathogenic conversion of Foxp3? T cells into TH17 cells in autoimmune arthritis" 20 : 62-68, 2014

31 Zielinski CE, "Pathogen-induced human TH17 cells produce IFN-gamma or IL-10 and are regulated by IL-1beta" 484 : 514-518, 2012

32 McAllister F, "Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia" 25 : 621-637, 2014

33 Rei M, "Murine CD27(-) Vgamma6(?) gammadelta T cells producing IL-17A promote ovarian cancer growth via mobilization of protumor small peritoneal macrophages" 111 : E3562-E3570, 2014

34 Calcinotto A, "Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression" 9 : 4832-, 2018

35 Gomes AL, "Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma" 30 : 161-175, 2016

36 Chang CH, "Metabolic competition in the tumor microenvironment is a driver of cancer progression" 162 : 1229-1241, 2015

37 Busch SE, "Lung cancer subtypes generate unique immune responses" 197 : 4493-4503, 2016

38 Sawa S, "Lineage relationship analysis of RORgammat ? innate lymphoid cells" 330 : 665-669, 2010

39 Akbay EA, "Interleukin-17A promotes lung tumor progression through neutrophil attraction to tumor sites and mediating resistance to PD-1 blockade" 12 : 1268-1279, 2017

40 Wang K, "Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis" 41 : 1052-1063, 2014

41 Zhang Q, "Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models" 72 : 2589-2599, 2012

42 Harrington LE, "Interleukin 17-producing CD4? effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages" 6 : 1123-1132, 2005

43 Garcia-Diaz A, "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression" 19 : 1189-1201, 2017

44 Buonocore S, "Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology" 464 : 1371-1375, 2010

45 Zhang JP, "Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients" 50 : 980-989, 2009

46 Balabko L, "Increased expression of the Th17-IL-6R/pSTAT3/ BATF/RorgammaT-axis in the tumoural region of adenocarcinoma as compared to squamous cell carcinoma of the lung" 4 : 7396-, 2014

47 Chen X, "Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients" 69 : 348-354, 2010

48 Hu X, "In vitro priming of adoptively transferred T cells with a RORgamma agonist confers durable memory and stemness in vivo" 78 : 3888-3898, 2018

49 Sharma P, "Immune checkpoint targeting in cancer therapy : toward combination strategies with curative potential" 161 : 205-214, 2015

50 Zhang Y, "Immune cell production of interleukin 17 induces stem cell features of pancreatic intraepithelial neoplasia cells" 155 (155): e213-, 2018

51 Khosravi N, "IL22 promotes Kras-Mutant lung cancer by induction of a protumor immune response and protection of stemness properties" 6 : 788-797, 2018

52 You R, "IL17A regulates tumor latency and metastasis in lung adeno and squamous SQ. 2b and AD. 1 cancer" 6 : 645-657, 2018

53 Furuta S, "IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells" 3 : 78ra31-, 2011

54 Jiang Z, "IL-25 blockade inhibits metastasis in breast cancer" 8 : 191-201, 2017

55 Langrish CL, "IL-23 drives a pathogenic T cell population that induces autoimmune inflammation" 201 : 233-240, 2005

56 Huber S, "IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine" 491 : 259-263, 2012

57 Kryczek I, "IL-22(?)CD4(?)T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L" 40 : 772-784, 2014

58 Ma S, "IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma" 74 : 1969-1982, 2014

59 Coffelt SB, "IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis" 522 : 345-348, 2015

60 Wang L, "IL-17 enhances tumor development in carcinogen-induced skin cancer" 70 : 10112-10120, 2010

61 Ha HL, "IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms" 111 : E3422-E3431, 2014

62 Wang L, "IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway" 206 : 1457-1464, 2009

63 Simoni Y, "Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency" 46 : 148-161, 2017

64 Hamai A, "Human T(H)17 immune cells specific for the tumor antigen MAGE-A3 convert to IFN-gamma-secreting cells as they differentiate into effector T cells in vivo" 72 : 1059-1063, 2012

65 Linnemann C, "High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4? T cells in human melanoma" 21 : 81-85, 2015

66 Wislez M, "High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras" 66 : 4198-4207, 2006

67 Wu HJ, "Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells" 32 : 815-827, 2010

68 Wolchok JD, "Guidelines for the evaluation of immune therapy activity in solid tumors : immune-related response criteria" 15 : 7412-7420, 2009

69 Chen Y, "Foxp3(?)regulatory T cells promote T helper 17 cell development in vivo through regulation of interleukin-2" 34 : 409-421, 2011

70 Yang Y, "Focused specificity of intestinal TH17 cells towards commensal bacterial antigens" 510 : 152-156, 2014

71 Hirota K, "Fate mapping of IL-17-producing T cells in inflammatory responses" 12 : 255-263, 2011

72 Blatner NR, "Expression of RORgammat marks a pathogenic regulatory T cell subset in human colon cancer" 4 : 164ra159-, 2012

73 Chung Y, "Expression and regulation of IL-22 in the IL-17-producing CD4? T lymphocytes" 16 : 902-907, 2006

74 Liu J, "ErbB2 pathway activation upon Smad4 loss promotes lung tumor growth and metastasis" 10 : 1599-1613, 2015

75 Kryczek I, "Endogenous IL-17 contributes to reduced tumor growth and metastasis" 114 : 357-359, 2009

76 Yosef N, "Dynamic regulatory network controlling TH17 cell differentiation" 496 : 461-468, 2013

77 Wilson NJ, "Development, cytokine profile and function of human interleukin 17-producing helper T cells" 8 : 950-957, 2007

78 Ma Y, "Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy" 208 : 491-503, 2011

79 Tosolini M, "Clinical impact of different classes of infiltrating T cytotoxic and helper cells(Th1, th2, treg, th17)in patients with colorectal cancer" 71 : 1263-1271, 2011

80 Kleinschek MA, "Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation" 206 : 525-534, 2009

81 Lotti F, "Chemotherapy activates cancerassociated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A" 210 : 2851-2872, 2013

82 Tran E, "Cancer immunotherapy based on mutation-specific CD4? T cells in a patient with epithelial cancer" 344 : 641-645, 2014

83 Schreiber RD, "Cancer immunoediting : integrating immunity’s roles in cancer suppression and promotion" 331 : 1565-1570, 2011

84 Pandiyan P, "CD4(?)CD25(?)Foxp3(?)regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model" 34 : 422-434, 2011

85 Simoni Y, "Bystander CD8(?)T cells are abundant and phenotypically distinct in human tumour infiltrates" 557 : 575-579, 2018

86 Bonertz A, "Antigenspecific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma" 119 : 3311-3321, 2009

87 WuL, "Anovel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis" 212 : 1571-1587, 2015

88 Chung AS, "An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy" 19 : 1114-1123, 2013

89 Bassolas-Molina H, "An RORgammat oral inhibitor modulates IL-17 responses in peripheral blood and intestinal mucosa of crohn’s disease patients" 9 : 2307-, 2018

90 Song X, "Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis" 40 : 140-152, 2014

91 Malchow S, "Aire-dependent thymic development of tumor-associated regulatory T cells" 339 : 1219-1224, 2013

92 Restifo NP, "Adoptive immunotherapy for cancer : harnessing the T cell response" 12 : 269-281, 2012

93 Grivennikov SI, "Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth" 491 : 254-258, 2012

94 Thelen TD, "Acute blockade of IL-25 in a colitis associated colon cancer model leads to increased tumor burden" 6 : 25643-, 2016

95 Chae WJ, "Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis" 107 : 5540-5544, 2010

96 Ciofani M, "A validated regulatory network for Th17 cell specification" 151 : 289-303, 2012

97 Tong Z, "A protective role by interleukin-17F in colon tumorigenesis" 7 : e34959-, 2012

98 Park H, "A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17" 6 : 1133-1141, 2005